Loading clinical trials...

Memantine as an Additive Therapy in Patients With Traumatic Brain Injury | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE2/PHASE3

Memantine as an Additive Therapy in Patients With Traumatic Brain Injury

NCT06914310•Mansoura University

Summary

Memantine has shown promise in mitigating secondary brain injury in previous studies. One study demonstrated that early memantine administration in moderate TBI patients resulted in lower serum neuron-specific enolase levels and improved Glasgow Coma Scale scores. However, other trials investigating memantine's impact on long-term cognitive function in TBI patients have yielded mixed results. There is a need for well-controlled studies to determine the efficacy of memantine in improving neurological and cognitive outcomes in patients with TBI.

Detailed Description

The current study aims to evaluate the cognitive function, neuroprotective effect, and S-100β serum level effect of Memantine in patients with mild to moderate traumatic brain injury (TBI) patients.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients between 18 and 70 years of age
•2. Patients mild (GCS 13-15) to moderate (GCS 9-12) TBI were assessed for the study eligibility.

Exclusion Criteria

•1. Comorbid illnesses, such as diabetes mellitus, ischemic heart disease, acute myocardial infarction within the past 48 hours.
•2. Acute or chronic renal insufficiency.
•3. Hepatic diseases.
•4. Autoimmune diseases.
•5. Malignancies.
•6. Pregnancy.
•7. Patients unable to tolerate enteral feeding.
•8. More than 24 hours (h) since traumatic injury

Locations (1)

Mansoura University

Al Mansurah, Dakahlia Governorate, Egypt

Key Dates

Start Date

March 25, 2025

Primary Completion Date

August 30, 2025

Completion Date

November 30, 2025

Last Updated

April 6, 2025

Enrollment

ESTIMATED participants

Conditions

Mild Traumatic Brain InjuryModerate Traumatic Brain Injury (TBI)

Interventions

Memantine

DRUG

Mannitol

DRUG

Auditory Plasticity Training

NCT06628505

Mild Traumatic Brain Injury

View study

RECRUITINGNA

Wearable Technology to Characterize and Treat mTBI Subtypes: Biofeedback-Based Precision Rehabilitation

NCT06381674

Mild Traumatic Brain Injury, ConcussionRehabilitation+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 6, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Memantine as an Additive Therapy in Patients With Traumatic Brain Injury

Inclusion Criteria

Exclusion Criteria

Auditory Plasticity Training

Wearable Technology to Characterize and Treat mTBI Subtypes: Biofeedback-Based Precision Rehabilitation

Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging

MindRhythm Detection of Concussion and Recovery Study

Randomized Controlled Trial of Treatment to Optimize Heart Rate Variability for Persistent Post-Concussion Symptoms

Facilitating Access to Specialty Treatment